Nicolas Schwenck

Head of Business Development and Partnerships, Ebenbuild GmbH

DIGITAL TWIN EVALUATES BREATHING DRIVEN LUNG DOSE

• Simulation of aerosol transport and regional deposition using CT-derived airway geometries and a physics-based whole-lung model

• Quantification of the local dose at the site of action across lung regions for pharmacopeial breathing assumptions and measured real-world breathing profiles

• Integration of in vitro aerosol characteristics from different aerosol-generating device classes: SMI, DPI and pMDI

• Device-class dependent differences in regional lung deposition identified across breathing patterns, enabling extension of the framework to virtual cohort studies for in silico evaluation of inhaled drug delivery

Ben Forbes

Professor of Pharmaceutics, King’s College London

How to characterise soft mist aerosols?

• Nasal Deposition

• Alberta Idealised Nasal Inlet

• Aerodynamic Particle Size Distribution

• Next Generation Impactor

• Effect of flow rate & Temperature

Tuncay Alan

Associate Professor, Monash University

PALM-A TUNEABLE LOW-STRESS AEROSOL PLATFORM

• Nozzle-free oscillating microchannel technology generates low-velocity (<1 m/s), low-shear aerosols

• Tuneable droplet size and plume characteristics deliver precise aerosol performance, achieving 93% fine particle fraction (NGI)

• The system delivers proteins and viscous formulations while preserving biological activity

• Adaptive dosing enables on-demand adjustment of output and droplet velocity, from low to high-throughput delivery

• Fully integrated handheld device combining microfluidics, actuation and electronic control, with cartridge-based delivery, designed for partner evaluation and scalable, low-cost manufacturing

Chantelle Ahlenstiel

Associate Professor, Kirby Institute, UNSW Sydney

RESPIRATORY DELIVERY PLATFORM FOR SIRNA THERAPEUTICS

• Optimised LNP formulation for respiratory delivery of siRNA

• Targeting the nasopharynx for upper respiratory tract virus infections

• Advancing respiratory models with ALI-cultures and live virus challenge 

• Safety and antiviral efficacy of siRNA-LNP in a SARS-CoV-2 mouse model

• Platform technology broadly applicable for respiratory disease

Madeline Zhang

PhD student, Van der Waals-Zeeman Institute, University of Amsterdam

IMPROVING AEROSOL DRUG DELIVERY IN THE ICU

• On-demand absolute humidification decouples gas flow humidification from heating while maintaining clinical safety threshold

• Reduced undesired deposition in breathing circuits through partial evaporation of drug droplets

• Bench measurements translated to deposited lung dose through simulations

• Increased delivered and deposited dose significantly for both high-flow nasal cannula (HFNC) and invasive mechanical ventilation (IMV) 

• Pulmonary diseases alter regional airway deposition, highlighting need for personalized aerosol therapy strategies

Darragh Murnane

Merxin Ltd

Building The Future Today: New Products In Development

Hao-Ying Li

Researcher, King’s College London

Targeted respiratory delivery enabled by controllable Rayleigh‑defined droplet sizes

• Elucidate the essence of the formation of LNP-mRNAs.

• Insights into the changes of LNP-mRNAs under shear stress (theoretically explain why VMN does not work)

• Soft mists for the delivery of LNP-mRNAs to targeted regions in nasal cavity

• Soft mists for the delivery of LNP-mRNAs to the lungs

• Some corrigendum of concepts